{'fraction_non_alphanumeric': 0.04709141274238227, 'fraction_numerical': 0.04293628808864266, 'mean_word_length': 4.830645161290323, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Megavoltage radiation therapy for supraglottic carcinoma. Results of treatment.

Case histories of 184 patients with supraglottic carcinomas treated by megavoltage radiotherapy were reviewed. Of the entire group consisting of 68% T3, and T4 lesions and 51% nodal metastases, a determinate three-year NED rate after radiation therapy was 38%. For T1, T2, T3, and T4 lesions, the determinate three-year NED rates were 89, 66, 21 and 23%, respectively. Patients without cervical nodes did considerably better than those with nodes (63% vs. 17%). Women appeared to respond to irradiation better than men, both with lesions in the early stages and without nodes (92% vs. 68%). The treatment policy of this disease is presented.